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Abstract. L-DOPA has been the gold standard treatment for Parkin-
son’s disease since 50 years. Being the direct biochemical precursor of
dopamine, L-DOPA is effectively converted in the brain, but two ma-
jor phenomena reduce its therapeutic action: i) competition with amino
acids in the gut wall and in the blood brain barrier and ii) its fast kinet-
ics (absorption, distribution, metabolism, and elimination). Continuous
administration of L-DOPA, such as jejunal pumps, have addressed the
issue of fast absorption. Considering a subcutaneous delivery of L-DOPA
allows to bypass the gastrointestinal tract and avoid competition with
dietary amino acids. Remains the competition at the blood barrier be-
tween amino acids and L-DOPA, which we address by proposing a closed-
loop controlled, continuous subcutaneous delivery pump. In the proof-of-
concept format, the delivery strategy evaluated on comprehensive model
of L-DOPA kinetics, holds the promise of improving the treatment of
late-stage Parkinson’s disease patients.
Keywords: PKPD, dynamical modeling, optimal control, Parkinson’s
disease, levodopa.
1 Introduction
L-DOPA (levodopa) is a naturally occurring precursor of dopamine in the hu-
man body [1]. The loss of dopaminergic neurons and the subsequent impaired
production of dopamine in the nigrostriatal region of the brain is the major cause
of pathogenesis and progression of Parkinson’s disease [2]. The supplementation
of L-DOPA is the gold standard in the treatment of Parkinson’s disease since
50 years. The efficacy of L-DOPA is hampered by its inherent fast kinetics. Af-
ter per os administration of a single dose, the peak of the concentration occurs
within an hour, after which a decrease in the concentration rapidly follows [1].
This kinetic profile leads to an on/off phenomena. The on phenomenon refers to
the periods when the symptoms are controlled. During such periods, dyskene-
sia (uncontrolled movements) might appear while the peak of the concentration
exceeds the upper limit of the therapeutic window [3]. The off phenomenon, or
akinesia, occurs when the concentration of L-DOPA drops below the therapeutic
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window. Patients report the inability to move and blockage, causing fall injuries
[4]. Other factors have been found to contribute to the on/off fluctuations, such
as diet, genetic variants, and stress [1]. The continuous intravenous administra-
tion of L-DOPA has been shown to be correlated with lower on/off phenomena
[5], which drove advances in L-DOPA formulation [3]. A continuous administra-
tion of L-DOPA gel through a jejunal pump, decreased the off-phenomena by
1.9 hours a day [6]. Although, it has been reported that continuous administra-
tion exacerbated adverse reactions related to levodopa, mainly the decrease in
folate, vitamin B12, and vitamin B6 as well as the increase in homocysteine and
methylmalonic acid, which induce neurological and metabolic dysfunctions [7].
Real-time controlled pumps are a new generation of drug delivery devices, which
take into account the physiology of patient as well as the drug concentrations to
deliver a personalized dose. Such devices allow for fast responses to unwanted
changes in order to keep drug levels within a predefined therapeutic window
[8]. Although subcutaneous blood concentration monitoring of L-DOPA is not
yet routinely done, non-invasive techniques have been developed and offer the
promise of a fast and reliable measurement of L-DOPA concentrations. Notably,
microdialysis, a minimally invasive technique, has been tested and increasingly
adopted in clinical practice for Parkinson’s disease patients under L-DOPA treat-
ment. Bypassing the small intestine through a subcutaneous infusion improved
the bioavailability of L-DOPA [9]. It has been shown that maintaining steady
state concentrations of L-DOPA through continuous infusion did not guarantee
achieving the clinical objectives, especially with proteic diet [10].
Taken together, (i) the fluctuations in the response to L-DOPA as well as (ii) its
gastrointestinal absorption characterized by erratic peaks, (iii) the adverse reac-
tions shown by the uncontrolled continuous jejunal delivery, and (iv) the failure
to improve the symptoms through only maintaining a steady concentrations of
plasma L-DOPA, make the subcutaneous controlled delivery pump a promis-
ing alternative for the treatment of Parkinson’s disease. To this end, a modified
molecule, L-DOPA methyl ester, was successfully administered through the sub-
cutaneous route [11]. The feedback control would ideally come from (i) measuring
L-DOPA concentrations in the plasma, (ii) resting tremor (hand shacking) as a
surrogate endpoint, and (iii) brain dopamine production.Since the latter mea-
surement needs invasive techniques, it should be reserved for patients subjected
to deep brain stimulation using implanted macroelectrodes that allow the mea-
surement of the local field potential (LFP) and the detection of brain power
spectrum correlated to on and off phenomena, as shown previously [12].
Here, we computationally model and analyse the behaviour of a novel subcu-
taneous delivery controlled pump based on comprehensive model of L-DOPA
kinetics and dynamics that merges two published models ([13] [1]), and compare
different control strategies (time invariant and continuous).
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2 Output measurements
The model describing L-DOPA is a combination of the pharmacokinetics [13]
and the pharmacodynamics [1] of the drug and consists of three state variables
X1(t), X2(t), and X3(t) that represent L-DOPA concentrations in the plasma,
tissues, and the brain respectively.
Presently, we will develop on the state variable X3(t) that is directly correlated
to the drug efficacy. It is assumed that the effect of the L-DOPA cannot be
measured directly, i.e., we cannot measure X3(t).
Instead, X3(t) can only be observed indirectly from the so called outputs. One
choice for an output is the effect corresponding on hand tapping; another choice
is the LFP measurements in patients equipped with deep brain stimulation de-
vices; a third alternative is X1(t), i.e., the plasma concentration. Measuring
X3(t) will not be further discussed, but the other two – hand tapping and LFP
– will now be addressed.
Hand tapping:
The concentration X3(t) can be directly estimated by the number of hand taps a
patient performs in a minute. A model of the hand taps was provided in [1] and
is given by E(t) = (h◦X3)(t) = EmaxX
n
3 (t)
ECn50 + X
n
3 (t)
+E0. The function h is implicitly
parametrized by Emaxs
n, ECn50, E0, and n. E(t) represents the effect. In this
situation, it is the number of taps per minute that the patient were asked to do
on buzzers separated by a distance of 20 cm. The integer n is the hill coefficient,
Emax is the maximum effect, and EC50 is the concentration of L-DOPA in the
effect compartment that gives 50% of the maximum effect.
The number of taps is measured as the number of times the patient could alter-
nately tap two buttons 20 cm apart in 60 seconds, with the most affected hand
[1]. The hand shacking is assumed to have a similar profile as the tapping test
if measured with an accelerometer or a similar body metric device.
It is also assumed that subcutaneous administration of L-DOPA yields the same
kinetics as the intravenous route. As a motivation for using the effect of hand
tapping to indirectly measure X3(t), it should be mentioned that wearable sen-
sors that can measure soft structures and body metrics are an active field of
research [14].
LFP measurements:
In this case, it is assumed that X3(t) can be approximated via LFP in patients
equipped with deep brain stimulation devices. Measuring the level of dopamine
in the brain is the ultimate efficacy indicator about disease progression and L-
DOPA efficacy. It has been reported that the increase of L-DOPA in the brain
is correlated with power spectrum modification in the LFP [12].
Dyskinetic patients showed a higher Gamma power in the LFP profile, while
akinetic patients have a Beta power profile. The change in the LFP profile has
been reported to correlate with a change in dopamine concentration in the brain
and dyskinesia [12].
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3 A comprehensive model of L-DOPA kinetics: Compact
notation
The model introduced can be represented by{
x˙ = Ax + Bu,
y = f(x),
(1)
where x(t) = [X1(t), X2(t), X3(t)]
T ∈ R+ are the state variables and u(t) =
[u1(t), u2(t)]
T is defined by u1(t) =
kc(t)
V1
+
Rsyn
(kelV1)
∈ R+, u2(t) = ke(t)V1 ∈ R+ with
Rsyn being the endogenous rate of synthesis, V1 the volume of blood compart-
ment, kel the clearance rate, kc(t) and ke(t) are the infusion rates in the central
and peripheral compartment respectively and y(t) is the output, i.e., states or
functions thereof, which are assumed to be measurable. The control variable u(t)
is introduced to be able to write the dynamics of x as a linear time invariant sys-
tem. In the end, it is the rate kc(t) = V1
(
u1(t)− Rsyn(kelV1)
)
that we want to choose.
x(t, t0, x0) is the solution to (1) with initial state x0 and initial time t0. There
are certain assumptions on the concentrations in the state x(t). It is assumed
that 0 ≤ x(t) ≤ v for all t, where v = [v1, v2, v3]T ∈ R3 of positive elements (the
vi); in this context “≤” means that the inequality should hold element-wise, and
“0” is a vector in R3 where the elements thereof are equal to zero. It is further
assumed that
Rsyn
(kelV1)
≤ u1(t), for all t. Without this assumption, the rate kc(t)
could take negative values, which is infeasible. The assumptions on y (or rather
f) lead to different control designs. The matrices A ∈ R3×3 and B ∈ R3×2 are
defined by
A =
−a11 a12 0a21 −a22 0
a31 0 −a33
 =
−(k12+kel)V1 k21V1 0k12
V2
−k21
V2
0
Dweight 0 −Ke0
 , B = [1 0 0
0 1 0
]T
,
where the aij are positive for all i, j, Dweight is the drug molecular weight, k12
and k21 are the inter-compartmental rates, V2 the peripheral volume, and Ke0
the blood to brain equilibration constant. The matrix A is assumed to be a stable
matrix, i.e., all the eigenvalues have strict negative real part [15,16].
4 Comparison of subcutaneous L-dopa infusion
Using the model in Section 3, we now compare two different strategies for ad-
ministration of levodopa: constant subcutaneous infusion and time-varying sub-
cutaneous infusion based on feedback. The infusion is only subcutaneous, i.e., we
design u2(t) and let the exogenous production term of u1(t) null for all t (or
equivalently kc(t) = 0 for all t).
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4.1 Constant infusion
The objective considered in here is to find a constant rate of infusion u2(t)
such that the concentration X3(t) converges asymptotically to a reference value,
which is kept within a therapeutic window. Formally, the problem is:
Problem 1. Given r3 ∈ R+, construct a control law u2(t) such that for any any
t0 ∈ R+ and x(t0) = x0 ∈ R3, X3(t) converges to r3 as t→∞.
Proposed solution to Problem 1:
u2(t) = −r˜2, u1(t) = 0, (2)
where r˜2 = a12r1 − a12r2, r1 = a33r3a31 , and r2 = a11r1a12 .
Explanation: The proposed solution is very simple and uses the structure of A.
It is also robust to small changes of the parameters of A. Let r = [r1, r2, r3]
T ∈
(R+)3 and [x˜1, x˜2, x˜3]T = x˜ = x − r. It holds that Ar = [0, r˜2, 0]T . Now, if we
choose u2(t) as in (2), the dynamics for x˜ is ˙˜x = Ax˜, which comprises a stable
system. Hence, x˜(t) converges asymptotically to r when t goes to the infinity,
which means that X3(t) converges to r3. Since there is no feedback, i.e., the
control law is constant, there is no need to address the issues of time-delays and
different time scales in the output. If the input u is slightly off, x3(t) converges to
a value that is close to r1. The most important thing to note is that continuous
supply of levodopa has the benefit of keeping the concentration at a constant
reference value, avoiding on/off behaviour.
4.2 Time-varying infusion and feedback
In this section, we assume that the reference signal is time-varying. Levodopa
requirements vary according to foreseeable events, such as circadian rhythm.
Patients need less levodopa during the night, although it is important to maintain
steady state concentrations to guarantee a better sleeping quality. In this case,
the therapeutic threshold is maintained during the day and decreased during
night. High protein diet is also a cause of time-variations in the reference signal:
the plasma concentration of levodopa stays stable, while brain concentrations
decrease because of competition for blood brain barrier carriers between levodopa
and dietary amino acids [3]. The structure of the measurements/outputs y(t)
determines the type of control designs considered. In this work we will focus
on the case when the measurements of X3(t) are available – the concentration
might be indirectly measured via the effect of hand tapping E3(t).
Problem 2. Given r3(t) ∈ R+, construct a control law u2(t) such that for any
any t0 ∈ R+ and x(t0) = x0 ∈ R3, X3(t) converges to r3(t) as t→∞.
Proposed Solution to Problem 2:
u2(t) = −z(t), u1(t) = 0. (3)
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where z˙(t) = kx˜3(t) = k(X3(t)− r3), z(t0) = 0 and k > 0. The larger the k, the
faster ‖x˜3(t)‖ converges to zero.
Explanation: Now we show that ‖x˜3(t)‖ converges to zero. In the following, all
symbols not explained can be found in Section 4.1. We see that ˙˜x = Ax˜+r˜2−z(t).
Let z˜ = r˜2 − z(t) and the augmented state vector be x˜aug(t) = [x˜(t)T , z˜]. Now
one can show that this closed loops dynamics has the properties that the x˜(t)T
vector converges to zero, which means that ‖x˜3(t)‖ converges to zero. Problem 2
is a trajectory tracking problem in a linear system. Since the system is in strict
feedback form one can use the backstepping control design technique [16]. There
are also various other methods that can be used. The proposed controller can be
modified in order to account for time delays and measurement errors in X3(t).
Appendix: Equations of L-DOPA kinetics
In order to provide the foundations for an L-DOPA control pump (Figure 2), a
comprehensive model is presented combining the drug kinetics with its effects
(pharmacodynamics) (Figure 1). The model consists of two compartments. The
first compartment describes the kinetics of L-DOPA following an intravenous
(IV) infusion. It also takes into account the synthesis of endogenous L-DOPA.
The parameters were identified by fitting the model onto patients’ plasma con-
centrations [13]. The second compartment of the model is a result of a study,
which focused on the pharmacodynamics of L-DOPA through measuring the
hand tapping score (number of taps per minute) with regard to L-DOPA plasma
concentration [1]. The dynamics were modeled using an Emax model linked to
an effect compartment. Patient stratification on Hoehn and Yahr (HY) disease
stage allowed to set thresholds for therapeutic efficiency for each stratum.
Fig. 1: Schematic of the closed loop controlled L-DOPA subcutaneous pump.
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Part 1 – kinetics
A two-compartmental, patient-validated model is used to model the kinetics of
L-DOPA [13].
Compartment 1 (Central compartment). The continuous infusion case is de-
scribed by the dynamical model:
dX1(t)
dt
=
(−(k12 + kel)X1(t)) + k21X2(t) + kc(t)
V1
+
Rsyn
(kelV1)
,
where X1(t) is the concentration of L-DOPA in the plasma, X2(t) the concentra-
tion of L-DOPA in the peripheral compartment (see below), and kc(t) is the rate
of infusion in the central compartment: k21 and k12 are the inter-compartmental
rates, kel is the elimination rate, Rsyn is the rate of production of endogenous
L-DOPA by the human body, V1 is the volume of central compartment;
Compartment 2 (Peripheral compartment).
dX2(t)
dt
=
(k12X1(t)− k21X2(t)) + ke(t)
V2
,
where V2 is the volume of the peripheral compartment, and ke(t) is the rate of
infusion in the peripheral compartment.
Fig. 2: Simulation of L-DOPA kinetics in different settings. (A) Kinetics of L-
DOPA in continuous subcutaneous infusion.(B) Cyclic infusion of L-DOPA based
on circadian rhythm. (C) Kinetics of brain and plasma L-DOPA in uncontrolled
subcutaneous administration with high protein diet, although the plasma con-
centrations are stable, concentrations in the brain decrease, which provided the
rationale for a closed loop subcutaneous infusion to retrieve a profile similar to
(A). HY1 refers to the first stage of the disease on Hoehn and Yahr’s scale.
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Part 2 – pharmacodynamics
The two compartments in Part 1 are complemented with an additional com-
partment – the effect compartment [1]. This compartment can be understood as
being analogous to the brain, where the drug has its effect.
Compartment 3 (Effect compartment).
dX3(t)
dt
= X1(t)−Ke0X3(t),
where X3(t) is the concentration of L-DOPA in the effect compartment, and
Ke0 the equilibration constant that accounts for the delay in reaching the site
of action.
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